Nancy K. Valente, M.D.

Nancy K. Valente, M.D.

Former Chief Development OfficeratXencor· In proxies 2023–2025

Pay in FY2025-85% from the year before · Xencor stock -33.4% the same year

Nancy K. Valente, M.D. was paid $430.8K in FY2025 (Dec), down 85%. Xencor stock fell 33.4% that year.

Pay$100 in the stock at the end of FY22 → $59
Pay is from the Summary Compensation Table of each Xencor proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. XencorPublic company · 3 yr
    • Former Chief Development Officer2023 – Present · 3 yrStock in role +19%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?